WallStreetZenWallStreetZen

NASDAQ: NKTR
Nektar Therapeutics Stock Ownership - Who owns Nektar Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Nektar Therapeutics insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Mark Andrew WilsonChief Legal Officer2025-05-199,996$0.67
$6.70kSell
Jonathan ZalevskyChief RD Officer2025-05-1910,712$0.67
$7.18kSell
Howard W. RobinPresident CEO2025-05-1923,208$0.67
$15.55kSell
Howard W. RobinPresident CEO2025-02-1923,774$1.01
$24.01kSell
Mark Andrew WilsonChief Legal Officer2025-02-1911,040$1.01
$11.15kSell
Jonathan ZalevskyChief RD Officer2025-02-1910,300$1.01
$10.40kSell
Mark Andrew WilsonChief Legal Officer2024-12-2416,560$0.89
$14.74kSell
Mark Andrew WilsonChief Legal Officer2024-12-2333,402$0.90
$30.06kSell
Jonathan ZalevskyChief RD Officer2024-12-1951,115$0.94
$48.05kSell
Howard W. RobinPresident CEO2024-12-1885,035$0.99
$84.18kSell

1 of 2

NKTR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when NKTR insiders and whales buy or sell their stock.

NKTR Shareholders

What type of owners hold Nektar Therapeutics stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Deep Track Capital LP147.85%18,344,000$157.57MInsider
Blackrock Inc126.60%15,707,325$134.93MInstitution
Vanguard Group Inc99.22%12,309,688$105.74MInstitution
Nantahala Capital Management LLC62.78%7,789,051$66.91MInstitution
Acadian Asset Management LLC58.85%7,301,734$62.72MInstitution
Eventide Asset Management LLC53.60%6,650,000$57.12MInstitution
Primecap Management Co43.16%5,354,586$46.00MInstitution
Renaissance Technologies LLC37.90%4,701,781$40.39MInstitution
Almitas Capital LLC37.16%4,610,872$39.61MInstitution
Geode Capital Management LLC32.31%4,009,124$34.44MInstitution

1 of 3

NKTR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NKTR82.53%17.47%Net SellingNet Selling
NTHI0.31%91.78%Net BuyingNet Buying
EXOZ0.56%99.44%Net Buying
CSBR2.00%98.00%Net Buying
ATOS21.95%11.04%Net BuyingNet Buying
View Top Biotech Stocks

Nektar Therapeutics Stock Ownership FAQ

Who owns Nektar Therapeutics?

Nektar Therapeutics (NASDAQ: NKTR) is owned by 998.09% institutional shareholders, 211.23% Nektar Therapeutics insiders, and 0.00% retail investors. Deep Track Capital LP is the largest individual Nektar Therapeutics shareholder, owning 18.34M shares representing 147.85% of the company. Deep Track Capital LP's Nektar Therapeutics shares are currently valued at $157.57M.

If you're new to stock investing, here's how to buy Nektar Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.